P.M.A. Calverley (Liverpool, United Kingdom), R. Buhl (Mainz, Germany), B. Cosio (Palma De Mallorca, Spain)
LATE-BREAKING ABSTRACT: Two Phase 3 placebo-controlled trials of Aztreonam Lysine for Inhalation (AZLI) for Non-Cystic Fibrosis Bronchiectasis (NCFB)
A. Barker, A. O'Donnell, P. J Thompson, P. Flume, J. Ruzi, J. de Gracia, W. Boersma, E. Polverino, L. Shao, J. Zhang, S. Leitzinger, L. Haas, M. McKevitt, A. B. Montgomery, A. Quittner, D. Gossage, T. O'Riordan (Portland, Washington DC, Charleston, Scottsdale, Foster City, Seattle, Miami, United States Of America; Nedlands, Australia; Barcelona, Spain; Alkmaar, Netherlands)
|   |
Differences in adherence to common inhaled medications in COPD
K. Koehorst-ter Huurne, K. Movig, P. vanderValk, J. van der Palen, M. Brusse-Keizer (Enschede, Netherlands)
| |
First dose response to tiotropium in COPD: Impact on dyspnea, lung hyperinflation and distal airways
J. Pastre, S. Fry, C. Fournier, A. Scherpereel, F. Denis, T. Perez (Lille, Paris, France)
| |
Cardio- and cerebro-vascular safety of QVA149: Results from a pooled analysis
G. T. Ferguson, N. Barnes, R. Mehta, P. D'Andrea, H. Chen, D. Banerji (Livonia, East Hanover, United States Of America; London, United Kingdom; Indore, India)
| |
Effect of tiotropium on exhaled breath temperature in patients with COPD
T. Kralimarkova, P. Georgieva, E. Mekov, D. Nedeva, V. Dimitrov, T. Popov (Sofia, Bulgaria)
| |
Integrated analyses of phase II safety data support the safety of glycopyrrolate-formoterol fumarate (GFF) MDI (PT003) and glycopyrrolate (GP) MDI (PT001) in COPD
R. Rodriguez-Roisin, L. Fabbri, C. Orevillo, C. Fernandez, P. Darken, E. St. Rose, T. Fischer, C. Kollar, C. Reisner (Barcelona, Spain; Modena, Italy; Redwood City, Little Falls, United States Of America)
| |
Limitations for the inclusion of patients in the Roflu-2011 study
A. Gómez-Bastero, A. Valido, C. Romero, P. Guerrero, L. Mechbal, T. Montemayor (Seville, Spain)
| |
Comparison of the efficacy and safety of long-acting anticholinergic and a combination of inhaled steroids and long-acting beta-2 agonist in moderate chronic obstructive pulmonary disease
P. Sarac, A. Sayiner (Izmir, Turkey)
| |
Real-life study on the aPpropriaTeness of treatment in moderate COPD patients (OPTIMO)
A. Rossi, M. Guerriero, A. Corrado, On Behalf of OPTIMO/AIPO Study Group (Verona, Firenze, Italy)
| |
Use of a new dry powder inhaler to deliver umeclidinium/vilanterol in the treatment of COPD
J. Riley, M. Tabberer, N. Richard, A. Donald, A. Church, S. Harris (Uxbridge, United Kingdom; Durham, United States Of America)
| |
The influence of type of inhalation device on adherence of COPD patients to inhaled medication
K. Koehorst-ter Huurne, K. Movig, P. vanderValk, J. van der Palen, M. Brusse-Keizer (Enschede, Netherlands)
| |
Cost effectiveness of budesonide/formoterol vs fluticasone/salmeterol: Real-world effectiveness and safety in COPD
M. Hedegaard, C. Janson, K. Lisspers, B. Ställberg, G. Johansson, L. Jörgensen, K. Larssen (Södertälje, Uppsala, Stockholm, Sweden)
| |
Effect of severe renal impairment (SRI) on umeclidinium (UMEC) and vilanterol (VI) pharmacokinetics (PK)
D. Kelleher, K. Hardes, N. Brealey, L. Tombs, A. Preece, R. Mehta (Research Triangle Park, United States Of America; Stockley Park, Slough, United Kingdom)
| |
Inhaled fluticasone propionate (FP) restores angiogenesis in the airway lamina propria of current smokers with COPD: A randomized controlled trial
S. S. Sohal, A. Soltani, D. Reid, H. K. Muller, R. Wood-Baker, E. H. Walters (Hobart, Brisbane, Australia)
| |
Effect of roflumilast on quality of life in frequent and infrequent exacerbators
P. Kardos, I. Makros, C. Vogelmeier (Frankfurt, Berlin, Marburg, Germany)
| |
Safety, immunogenicity and pharmacokinetics (PK) of a 120 mg/kg/week dose of alpha1-proteinase inhibitor in alpha1-antitrypsin deficiency
M. Campos, F. Kueppers, J. Stocks, C. Strange, J. Chen, R. Griffin, L. Wang-Smith, M. Cruz, P. Vandeberg, M. Brantly (Miami, Philadelphia, Tyler, Charleston, , Gainesville, United States Of America)
| |
Examination of variations in responder rates in COPD clinical trial outcomes
P. Jones, M. Decramer, J. A. Wedzicha, D. Banerji (London, United Kingdom; Leuven, Belgium; East Hanover, United States Of America)
| |
Pooled analyses of five phase 2b studies support dose selection of glycopyrrolate-formoterol (GFF) MDI (PT003) 18/9.6 μg for phase III development
C. Reisner, C. Orevillo, C. Fernandez, P. Darken, E. St. Rose, M. Golden, T. Fischer, S. Strom, C. Kollar, K. F. Rabe (Redwood City, Little Falls, United States Of America; Grosshansdorf, Germany)
| |
Bronchial hyperresponsiveness as a predictor of treatment-response in COPD
I. Trofimenko, B. Chernyak (Irkutsk, Russian Federation)
| |
COPD treatment defaulters in tertiary care hospital in suburban India: Reasons for treatment interruptions, its prevalence and predictors
A. Javia, D. Mehta, F. Ganchi, D. Patel (Jamnagar, Karamsad, India)
| |